US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
CA2545539A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
CN102746404B
(en)
|
2004-11-12 |
2016-01-20 |
赞科股份有限公司 |
To FcRn in conjunction with reformed Fc variant
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
EP1931709B1
(en)
|
2005-10-03 |
2016-12-07 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
CA2625998C
(en)
|
2005-10-06 |
2015-12-01 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
DK3056568T3
(en)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
PROCEDURES FOR CONTROL OF THE BLOOD PHARMACOKINETICS OF ANTIBODIES
|
DK2383297T5
(en)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimized antibodies directed against CD19
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
CL2008002886A1
(en)
|
2007-09-26 |
2009-12-04 |
Chugai Pharmaceutical Co Ltd |
Constant region of a human antibody; anti-interleukin-6 (yl-6) receptor antibody and pharmaceutical composition comprising it.
|
SI2808343T1
(en)
|
2007-12-26 |
2019-10-30 |
Xencor Inc |
Fc variants with altered binding to FcRn
|
US8039596B2
(en)
|
2008-02-05 |
2011-10-18 |
Bristol-Myers Squibb Company |
Alpha 5-beta 1 antibodies and their uses
|
KR102469853B1
(en)
|
2008-04-11 |
2022-11-22 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US8722860B2
(en)
|
2009-04-16 |
2014-05-13 |
Abbvie Biotherapeutics Inc. |
Anti-TNF-α antibodies and their uses
|
MX346002B
(en)
|
2009-06-17 |
2017-03-01 |
Abbvie Biotherapeutics Inc |
Anti-vegf antibodies and their uses.
|
CN102741422B
(en)
|
2009-08-24 |
2016-06-08 |
阿穆尼克斯运营公司 |
Factor VII composition and preparation and application thereof
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
BR112012010202A2
(en)
|
2009-11-02 |
2015-09-22 |
Univ Washington |
dimeric polypeptide hybrid nuclease molecule, pharmaceutical composition nucleic acid molecule recombinant expression vector transformed host cell method for preparing the nuclease molecule and method for treating or preventing a condition associated with an abnormal immune
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
US8642557B2
(en)
|
2010-03-12 |
2014-02-04 |
Abbvie Biotherapeutics Inc. |
CTLA4 proteins and their uses
|
KR101380840B1
(en)
|
2010-04-01 |
2014-04-04 |
한국생명공학연구원 |
Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer
|
MX2013000301A
(en)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Chimeric clotting factors.
|
AU2011337704B2
(en)
|
2010-11-30 |
2017-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
MX352889B
(en)
|
2011-02-25 |
2017-12-13 |
Chugai Pharmaceutical Co Ltd |
Fcîriib-specific fc antibody.
|
PL2704737T3
(en)
|
2011-04-29 |
2018-07-31 |
University Of Washington |
Therapeutic nuclease compositions and methods
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
UY34317A
(en)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
T cell antireceptor antibody (alpha) / ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013047748A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
TW201817745A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
|
WO2013047752A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Antigen-binding molecule for promoting loss of antigens
|
WO2013081143A1
(en)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
Drug containing carrier into cell for forming immune complex
|
TWI640537B
(en)
|
2011-12-05 |
2018-11-11 |
X 染色體有限公司 |
Pdgf receptor beta binding polypeptides
|
BR112014017165B1
(en)
|
2012-01-12 |
2023-05-02 |
Bioverativ Therapeutics Inc |
CHIMERIC PROTEIN COMPRISING A FACTOR VIII PROTEIN, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
|
JP6256882B2
(en)
|
2012-02-15 |
2018-01-10 |
アムニクス オペレーティング インコーポレイテッド |
Factor VIII composition, and method of making and use of the composition
|
JP6383666B2
(en)
|
2012-02-15 |
2018-08-29 |
バイオベラティブ セラピューティクス インコーポレイテッド |
Recombinant factor VIII protein
|
JP6138108B2
(en)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
Antigen-binding molecule that promotes disappearance of antigen via FcγRIIB
|
TWI605060B
(en)
|
2012-03-28 |
2017-11-11 |
賽諾菲公司 |
Antibodies to bradykinin b1 receptor ligands
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
CA2872856A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
JP2015521589A
(en)
|
2012-06-08 |
2015-07-30 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Procoagulant compounds
|
EP2870250B2
(en)
|
2012-07-06 |
2022-06-29 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor viii polypeptides and uses thereof
|
SG10201913893XA
(en)
|
2012-07-11 |
2020-03-30 |
Bioverativ Therapeutics Inc |
Factor viii complex with xten and von willebrand factor protein, and uses thereof
|
HUE056217T2
(en)
|
2012-07-13 |
2022-02-28 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
SG10201709559PA
(en)
|
2012-08-24 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
PT3366705T
(en)
|
2012-09-12 |
2023-07-19 |
Genzyme Corp |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
MX2015003541A
(en)
|
2012-09-19 |
2015-10-26 |
Abbvie Biotherapeutics Inc |
Methods for identifying antibodies with reduced immunogenicity.
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
EP3889173B1
(en)
|
2013-02-15 |
2023-07-05 |
Bioverativ Therapeutics Inc. |
Optimized factor viii gene
|
IL275376B2
(en)
|
2013-03-11 |
2024-01-01 |
Genzyme Corp |
Hyperglycosylated binding polypeptides
|
CA2899089C
(en)
|
2013-03-15 |
2021-10-26 |
Biogen Ma Inc. |
Factor ix polypeptide formulations
|
RU2015144033A
(en)
|
2013-03-15 |
2017-04-26 |
Эббви Байотекнолоджи Лтд. |
ANTIBODIES AGAINST CD25 AND THEIR APPLICATION
|
JP2016515524A
(en)
|
2013-03-15 |
2016-05-30 |
アッヴィ バイオテクノロジー リミテッド |
Anti-CD25 antibodies and their use
|
CN105143257B
(en)
|
2013-03-15 |
2020-10-27 |
艾伯维生物医疗股份有限公司 |
FC variants
|
US11267868B2
(en)
|
2013-04-02 |
2022-03-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
EP3043813B1
(en)
|
2013-08-08 |
2021-01-13 |
Bioverativ Therapeutics Inc. |
Purification of chimeric fviii molecules
|
SG10201710013RA
(en)
|
2013-08-13 |
2018-01-30 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
|
TW201722994A
(en)
|
2013-08-13 |
2017-07-01 |
賽諾菲公司 |
Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and uses thereof
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
EP3048899B1
(en)
|
2013-09-25 |
2021-09-08 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
US10988745B2
(en)
|
2013-10-31 |
2021-04-27 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
RS63583B1
(en)
|
2014-01-10 |
2022-10-31 |
Bioverativ Therapeutics Inc |
Factor viii chimeric proteins and uses thereof
|
SG10201808158UA
(en)
|
2014-03-19 |
2018-10-30 |
Genzyme Corp |
Site-specific glycoengineering of targeting moieties
|
CA2943242A1
(en)
|
2014-03-21 |
2015-09-24 |
X-Body, Inc. |
Bi-specific antigen-binding polypeptides
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
AP2017009826A0
(en)
|
2014-09-26 |
2017-03-31 |
Bayer Pharma AG |
Stabilized adrenomedullin derivatives and use thereof
|
CA2964123C
(en)
|
2014-10-09 |
2023-09-05 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
NZ730563A
(en)
|
2014-10-14 |
2019-05-31 |
Halozyme Inc |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
KR20170110129A
(en)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
Antibodies comprising ionic concentration dependent antigen binding domains, Fc region variants, antibodies that bind to IL-8, and their use
|
EP3265483B1
(en)
|
2015-03-06 |
2019-12-11 |
CSL Behring Lengnau AG |
Modified von willebrand factor having improved half-life
|
WO2017011592A1
(en)
|
2015-07-13 |
2017-01-19 |
Modular Genetics, Inc. |
Generation of acyl alcohols
|
BR112018002150A2
(en)
|
2015-08-03 |
2018-09-18 |
Bioverativ Therapeutics Inc |
factor ix fusion proteins and methods of manufacturing and using them
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
JP2019500327A
(en)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
Anti-huLRRC15 antibody drug conjugate and method of use thereof
|
WO2017095808A1
(en)
|
2015-11-30 |
2017-06-08 |
Abbvie Inc. |
ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
EP3184544A1
(en)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein v inhibitors for use as coagulants
|
DK3411478T3
(en)
|
2016-02-01 |
2022-09-12 |
Bioverativ Therapeutics Inc |
OPTIMIZED FACTOR VIII GENES
|
KR20230028574A
(en)
|
2016-05-17 |
2023-02-28 |
애브비 바이오테라퓨틱스 인크. |
ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
|
JP2019523221A
(en)
|
2016-05-27 |
2019-08-22 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Anti-CD40 antibodies and uses thereof
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
EP3464367B1
(en)
|
2016-05-27 |
2020-09-09 |
AbbVie Biotherapeutics Inc. |
Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
|
MA45554A
(en)
|
2016-07-01 |
2019-05-08 |
Resolve Therapeutics Llc |
OPTIMIZED BINUCLEASE FUSIONS.
|
CN116251182A
(en)
|
2016-08-05 |
2023-06-13 |
中外制药株式会社 |
Compositions for preventing or treating IL-8 related diseases
|
HUE051700T2
(en)
|
2016-09-14 |
2021-03-29 |
Abbvie Biotherapeutics Inc |
Anti-pd-1 antibodies
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
TWI788307B
(en)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
|
BR112019011198A2
(en)
|
2016-12-02 |
2019-12-17 |
Bioverativ Therapeutics Inc |
methods of inducing immune tolerance to coagulation factors
|
IL266972B2
(en)
|
2016-12-02 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
KR20210157471A
(en)
|
2016-12-15 |
2021-12-28 |
애브비 바이오테라퓨틱스 인크. |
Anti-ox40 antibodies and their uses
|
US20200121719A1
(en)
|
2017-01-06 |
2020-04-23 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
TW201836647A
(en)
|
2017-04-06 |
2018-10-16 |
美商艾伯維有限公司 |
Anti-prlr antibody-drug conjugates (adc) and uses thereof
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
CN111247251A
(en)
|
2017-08-09 |
2020-06-05 |
比奥维拉迪维治疗股份有限公司 |
Nucleic acid molecules and uses thereof
|
SG11202001311VA
(en)
|
2017-08-22 |
2020-03-30 |
Sanabio Llc |
Soluble interferon receptors and uses thereof
|
CA3083118A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
JP2021508104A
(en)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Systems and methods for determining beneficial administration of tumor-infiltrating lymphocytes and their use, as well as beneficial administration of tumor-infiltrating lymphocytes and their use.
|
BR112020015228A2
(en)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
USE OF LENTIVIRAL VECTORS THAT EXPRESS FACTOR VIII
|
CA3090795A1
(en)
|
2018-02-13 |
2019-08-22 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
TW202003034A
(en)
|
2018-03-13 |
2020-01-16 |
英商塔斯克療法有限公司 |
Anti-CD25 antibody agents
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
EA202092316A1
(en)
|
2018-03-28 |
2021-05-25 |
Бристол-Маерс Сквибб Компани |
FUSION PROTEINS OF INTERLEUKIN-2 / ALPHA-RECEPTOR OF INTERLEUKIN-2 AND METHODS OF APPLICATION
|
MA52630A
(en)
|
2018-05-18 |
2021-05-26 |
Bioverativ Therapeutics Inc |
HEMOPHILIA A TREATMENT METHODS
|
EP3800999A4
(en)
|
2018-06-04 |
2022-06-01 |
Biogen MA Inc. |
Anti-vla-4 antibodies having reduced effector function
|
JP2021529763A
(en)
|
2018-07-03 |
2021-11-04 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
FGF-21 preparation
|
EP3833766A1
(en)
|
2018-08-09 |
2021-06-16 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
TW202031273A
(en)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
Treatment of nsclc patients refractory for anti-pd-1 antibody
|
KR20210091212A
(en)
|
2018-11-05 |
2021-07-21 |
이오반스 바이오테라퓨틱스, 인크. |
Treatment of NSCLC Patients Refractory to Anti-PD-1 Antibodies
|
MX2021008081A
(en)
|
2019-01-04 |
2021-08-05 |
Resolve Therapeutics Llc |
Treatment of sjogren's disease with nuclease fusion proteins.
|
KR20210136050A
(en)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
Expansion of tumor-infiltrating lymphocytes from liquid tumors and their therapeutic use
|
MA55529A
(en)
|
2019-04-03 |
2022-02-09 |
Genzyme Corp |
REDUCED FRAGMENTATION ANTI-ALPHA BETA TCR BINDING POLYPEPTIDES
|
JP2022537369A
(en)
|
2019-06-18 |
2022-08-25 |
バイエル アクチェンゲゼルシャフト |
Adrenomedullin-analogs and their use for long-term stabilization
|
US20210113634A1
(en)
|
2019-09-30 |
2021-04-22 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
CA3164818A1
(en)
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
CN115362167A
(en)
|
2020-02-06 |
2022-11-18 |
百时美施贵宝公司 |
IL-10 and uses thereof
|
IL295590A
(en)
|
2020-02-28 |
2022-10-01 |
Genzyme Corp |
Modified binding polypeptides for optimized drug conjugation
|
CN115315446A
(en)
|
2020-03-06 |
2022-11-08 |
Go医疗股份有限公司 |
anti-sugar-CD 44 antibodies and uses thereof
|
EP4171614A1
(en)
|
2020-06-29 |
2023-05-03 |
Resolve Therapeutics, LLC |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
EP4255933A1
(en)
*
|
2020-12-07 |
2023-10-11 |
Invetx, Inc. |
Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
JP2023554395A
(en)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Treatment with tumor-infiltrating lymphocyte therapy in combination with CTLA-4 and PD-1 inhibitors
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
JP2024501845A
(en)
|
2020-12-31 |
2024-01-16 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Devices and processes for automated production of tumor-infiltrating lymphocytes
|
UY39610A
(en)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
ANTI-EGFR ANTIBODY-DRUG CONJUGATES
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
EP4301782A1
(en)
|
2021-03-05 |
2024-01-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
EP4301138A2
(en)
|
2021-03-05 |
2024-01-10 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
CA3212439A1
(en)
|
2021-03-19 |
2022-09-22 |
Michelle SIMPSON-ABELSON |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
CA3213080A1
(en)
|
2021-03-23 |
2022-09-29 |
Krit RITTHIPICHAI |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
KR20240032711A
(en)
|
2021-03-25 |
2024-03-12 |
이오반스 바이오테라퓨틱스, 인크. |
Methods and compositions for use in T-cell co-culture efficacy assays and cell therapeutics
|
KR20240037185A
(en)
|
2021-04-19 |
2024-03-21 |
이오반스 바이오테라퓨틱스, 인크. |
Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CA3221735A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
WO2023014863A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CA3230934A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
TW202325733A
(en)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
Anti-glyco-lamp1 antibodies and their uses
|
AU2022343729A1
(en)
|
2021-09-09 |
2024-03-21 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
AR127482A1
(en)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
US20240101691A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|